TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00929578
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralesional injection of placebo
Study: NCT04390698
Drug: opioid free anesthesia
Normalized name: acid red 337 free acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: propofol, lidocine and muscle relaxant will be used for induction, after laryngeal mask airway insertion, general anesthesia will be maintained.
Study: NCT00081289
Drug: Capecitabine 1200 mg/m^2/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg/m\^2 q12 hours(1200 mg/m\^2/day) orally 5 days per week during radiotherapy.
Study: NCT00081289
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-fluorouracil bolus 400 mg/m\^2 IV push Day 1 (postoperatively), every 14 days, for nine 14-day cycles.~5-fluorouracil infusion 2400 mg/m\^2 IV continuous infusion over 46 hours, beginning day 1, every 14 days, for nine 14-day cycles.
Study: NCT01019590
Drug: Olmesartan Medoxomil and Hydrochlorothiazide Tablets 40 mg/25 mg
Normalized name: hydrochlorothiazide / olmesartan medoxomil Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01019590
Drug: Benicar HCT ® Tablets 40 mg/25 mg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00916721
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Visit 2 (first smoking-related memory reactivation session) the subject will be given 0.67 mg/kg (minimum 40 mg; maximum 80 mg) of short-acting propranolol (or placebo) rounded to the nearest 10 mg. Ninety minutes after this dose, if subject has tolerated the short-acting dose well, and if systolic blood pressure has not fallen by 10 mmHg or more to below 100 mmHg, the subject will be given oral long-acting propranolol 1 mg/kg (minimum 60 mg; maximum 120 mg) or placebo rounded to the nearest 20 mg. . If the subject tolerates the combination dose well, during treatment phase (from visit 7 to 12), both the short- and long-acting doses will be given together immediately prior to memory reactivation.
Study: NCT04331730
Drug: AKST4290
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral AKST4290
Study: NCT04331730
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral placebo
Study: NCT01466478
Drug: Ointment B: LEO 29102 2.5 mg/g ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: once daily application, 4 weeks
Study: NCT03073395
Drug: [68Ga]P16-093
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imaging by Positron Emission Tomography after iv injection of \[68Ga\]P16-093
Study: NCT03904576
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Film-coated tablet
Study: NCT02145767
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02133014
Drug: 0.5% 5-fluorouracil normal saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: On the one hand,0.5% 5-fluorouracil normal saline directly inhibit DNA synthesis of pancreatic acinar cells which result in the synthesis of amylopsin of and trypsase is restrained.On the other hand,it can induce pancreatic cells apoptosis and alleviate pancreatic necrosis.
Study: NCT00318201
Drug: Erythromycin
Normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00049413
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02468089
Drug: GMCSF (of Granulocyte-Monocyte Colony-Stimulating Factor) .
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03729869
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One dose of matched placebo twice a day.
Study: NCT00883194
Drug: PRF-108
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine
Study: NCT00883194
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRF-108 Placebo
Study: NCT00883194
Drug: PRF-110
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00144105
Drug: TPV500mg/RTV200mgBID
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00893113
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfuzosin-matched One tablet once daily
Study: NCT02974257
Drug: Thiamine
Normalized name: Thiamine
DrugBank: Thiamine (DB00152)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Thiamine 500mg IV twice daily for 2 days
Study: NCT00403117
Drug: Placebo + Inactive Marijuana (0% THC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: One capsule containing placebo was administered to the participant in a size 00 opaque capsules with lactose filler 45 minutes before marijuana administration.
Study: NCT00403117
Drug: Placebo + Active Marijuana (3.27% THC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: One capsule containing placebo was administered to the participant in a size 00 opaque capsules with lactose filler 45 minutes before administration of a marijuana cigarette containing 3.27% THC (ca. 800 mg) provided by the National Institute on Drug Abuse.
Study: NCT01707823
Drug: acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT00077987
Drug: SU011248
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01654562
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simvastatin 40mg daily by mouth for 5 weeks (4-6 week window) followed by 5 week washout period (4-6 week window).
Study: NCT01997567
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 2 consented subjects will receive for their hip arthroscopy procedures general anesthesia (sevoflurane) with single femoral and lateral femoral cutaneous nerve blocks under ultrasound guidance, with 20 ml solution for the femoral block and 10 ml for lateral femoral cutaneous block, for a total of 30 ml solution of saline with epinephrine 1:200,000 (150 mcg) (total 30 ml)
Study: NCT01115946
Drug: ASP1585
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT03774745
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects randomized to placebo receive treatment starting day 2.
Study: NCT02268565
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: pill that looks like aspirin without the effects of aspirin
Study: NCT03864913
Drug: Testosterone injection
Normalized name: testosterone Injection
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SQ or IM testosterone injections for pubertal induction of transgender male adolescents. Increasing doses per protocol at 3 month and 6 month follow up.
Study: NCT02778880
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03074162
Drug: Diclofenac Sodium
Normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: twice daily
Study: NCT00890682
Drug: SKY0402
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local infiltration of 8cc SKY0402
Study: NCT00592150
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo infusion for 3 hours
Study: NCT00849693
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules identical in appearance, color, taste, and smell to study drug, orally, once daily for 10 weeks (acute treatment phase)
Study: NCT00849693
Drug: fluoxetine
Normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20 milligram (mg) orally, once daily for 10 weeks (acute treatment phase) and 20-40 mg orally, once daily for additional 6 months (extension phase)
Study: NCT00890682
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local infiltration of 8cc Placebo
Study: NCT02905110
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate 4 mg into fourth ventricle of the brain via the Ommaya Reservoir 2 days a week for 6 weeks. Each patient will have 12 infusions.
Study: NCT02952547
Drug: DWJ1366 Tab.
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03229746
Drug: azathioprine
Normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: dose 100mg daily for at least 3 weeks
Study: NCT01586663
Drug: Drug treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: This patients will keep there drug treatment and will receive their splints on the end of the study.
Study: NCT03690414
Drug: Experimental BHVI2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental BHVI2 eye drops
Study: NCT02928393
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matched to basmisanil immediate-release granules will be given orally twice daily for 90 days.
Study: NCT00359814
Drug: Mycophenolatmofetile
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mycophenolatmofetile administration: was started with 250 mg/daily at day 1, the start dose was increased about 250 mg/daily every week till 2 g/daily
Study: NCT04594408
Drug: Epinephrine
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 mL of 1:1000 mixed into irrigation bag.
Study: NCT04594408
Drug: Epinephrine and Tranexamic Acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 mL of 1:1000 epinephrine mixed into irrigation bag, and 1 g tranexamic acid x 1 dose to be administered intraoperatively.
Study: NCT02369978
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two capsules of matching placebo (contaning Magnesium stearate and cellulose) B.I.D
Study: NCT03802422
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided hydrodissection with 3cc 0.9% normal saline between carpal tunnel and median nerve.
Study: NCT04635527
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: before surgery placebo intravenous injection Q2W,after surgery placebo intravenous injection Q4W
Study: NCT02393599
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg 2 times per day from Day 3 to 9 and one time on Day 10
Study: NCT00718861
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00718861
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT04618497
Drug: Ketorolac
Normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Each patient in the ketorolac group will receive one dose of 30mg intramuscular ketorolac injected at gluteal muscle by nursing staff as usual daily practice.
Study: NCT04616430
Drug: Topical endoxifen
Approvals — FDA: no, EMA: no, PMDA: no
Description: topical solution
Study: NCT04616430
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: topical
Study: NCT02296229
Drug: androgen deprivation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: up to 9 months at the discretion of the treating physician
Study: NCT04125134
Drug: Preservative-free Refresh Optive Advanced Lubricant Eye Drops
Approvals — FDA: no, EMA: no, PMDA: no
Description: over the counter artificial tear
Study: NCT05169450
Drug: Ginaton
Normalized name: Genaton
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive intravenously administered Ginaton, combined with guidelines-based standard care.
Study: NCT00756977
Drug: BLI850
Approvals — FDA: no, EMA: no, PMDA: no
Description: multi-dose preparation for oral administration prior to colonoscopy
Study: NCT04115397
Drug: Zoledronic Acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Treating seropositive individuals with musculoskeletal symptoms with one infusion zolendronic acid as compared to placebo
Study: NCT04115397
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01558089
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: according to SmPC and clinical practice
Study: NCT02571179
Drug: intranasal fentanyl 50 microg dose up to 250 microg
Normalized name: fentaNYL Metered Dose Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: When contraction pain was ≥ 5/10 (numerical rating scale 0= no pain, 10= worst pain), the parturient was given a intranasal fentanyl 50 µg dose. After 15 minutes, if contraction pain was still ≥ 5/10, a second 50 µg intranasal dose was administered. Fentanyl was administered every 15 minute until contraction pain decreased to less than 5/10 or until the maximum fentanyl dose of 250 µg was administered.
Study: NCT03465735
Drug: Standard of Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticoagulant therapy will be decided by physician and patient.
Study: NCT01884285
Drug: Part A: AZD8186 monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: The initial schedule will use intermittent dosing of AZD8186. Dose, frequency and schedule in subsequent cohorts may be modified in response to safety, tolerability, pharmacokinetic and preclinical data.
Study: NCT01884285
Drug: Part B: AZD8186 monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part B will be at a dose(s) and schedule(s) at or below from Part A
Study: NCT01884285
Drug: Part D1: AZD2014 combination with AZD8186
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose \& schedule finding of AZD8186 in combination with AZD2014
Study: NCT03766997
Drug: Hydrocortisone Butyrate 0.1% Cream
Normalized name: HYDROCORTISONE BUTYRATE 0.1% CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: topical use
Study: NCT02112604
Drug: Sedatives and muscle relaxants given in the ICU
Normalized name: MUSCLE RELAXANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in the ICU are administered sedatives, anesthetics, opiods, anti-pyschotics and neuromuscular blocking agents as part of routine care. We hypothesize that the use of these drugs is associated with sleep-disordered breathing following extubation. We will collect the drug doses from the patient's chart.
Study: NCT00192517
Drug: MEDI-522
Normalized name: Medi-Lyte
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg/kg (for 12 weeks based on patient's weight, to the nearest kg, obtained on Study Day 0)
Study: NCT04064684
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enrolled patients will be treated with normal saline.The medication will be administered to the patient by the respiratory therapist with the single-patient-use medication nebulizer attached to the mechanical ventilator circuit. The maximum length of treatment will be 10 days.
Study: NCT03567499
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo capsules to match active 100 mg and 200 mg dose strength will be available and to be taken as single or multiple capsules orally along with water depending on the number of active capsules to blind.
Study: NCT03117049
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo solution intravenously for 30 min in every 3 weeks until RECIST 1.1 defined PD, unacceptable toxicity, or withdrawal of consent.
Study: NCT00195559
Drug: Levonorgestrel/Ethinyl Estradiol
Normalized name: levonorgestrel/ethinyl estradiol 0.1 mg-20 mcg ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01713400
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection of sterile saline (identical volume to that of ustekinumab) administered via the identical route and schedule as ustekinumab.
Study: NCT00121810
Drug: mycophenolate mofetil [CellCept]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0-1.5 g oral dose twice daily
Study: NCT00121810
Drug: Corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: As prescribed
Study: NCT00121810
Drug: Calcineurin inhibitors
Normalized name: Calcineurin inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: As prescribed
Study: NCT00365976
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo nightly over duration of double blind study phase
Study: NCT00828867
Drug: 100 mg GSK investigational drug
Normalized name: INVESTIGATIONAL THROMBOLYTIC DRUGS
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00828867
Drug: 200 mg GSK investigational drug
Normalized name: INVESTIGATIONAL THROMBOLYTIC DRUGS
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00828867
Drug: 400 mg GSK investigational drug
Normalized name: INVESTIGATIONAL THROMBOLYTIC DRUGS
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00828867
Drug: 800 mg GSK investigational drug
Normalized name: INVESTIGATIONAL THROMBOLYTIC DRUGS
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00828867
Drug: 2000 mg GSK investigational drug
Normalized name: INVESTIGATIONAL THROMBOLYTIC DRUGS
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00828867
Drug: 1500 mg GSK investigational drug
Normalized name: INVESTIGATIONAL THROMBOLYTIC DRUGS
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00828867
Drug: 800mg fed GSK investigational drug
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00828867
Drug: 3000mg GSK investigational drug
Normalized name: INVESTIGATIONAL THROMBOLYTIC DRUGS
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00828867
Drug: 4000mg GSK investigational drug
Normalized name: INVESTIGATIONAL THROMBOLYTIC DRUGS
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04676139
Drug: Fluoxetine
Normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluoxetine 10 mg capsules once daily for 12 months
Study: NCT04676139
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo for 12 months
Study: NCT00053820
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00073593
Drug: Heparin
Normalized name: Heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: : Per institutional practice, at 1.5-3.5 mg/kg (200-400 U/kg) IV bolus to achieve a target ACT of \>300 s followed by weight-adjusted boluses as needed during surgery to achieve/maintain the target ACT. Batches from hospital stock.
Study: NCT06671431
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy with or without radiotherapy
Study: NCT00308295
Drug: matched placebo capsules
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00972998
Drug: Phenyephrine
Normalized name: CTM 4/IBUPRO 200/PHENYEPHRINE 10MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenyephrine coated suppositories
Study: NCT02014116
Drug: LY3009120 capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally.
Study: NCT01970033
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Run in period ：oral tablets of Placebo twice daily for 2 weeks~* Phase A : oral tablets of Placebo twice daily for 24 weeks~* Phase B : SP2086 50 mg b.i.d or SP2086 100 mg q.d. for 28 weeks
Study: NCT01970033
Drug: SP2086 50 mg b.i.d.
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Run-in period: placebo twice daily for 2 weeks~* Phase A:SP2086 50 mg b.i.d for 24 weeks~* Phase B:SP2086 50 mg b.i.d for 28 weeks
Study: NCT01970033
Drug: SP2086 100 mg q.d.
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Run-in period:placebo twice daily for 2 weeks~* Phase A: SP2086 100 mg q.d. for 24 weeks~* Phase B: SP2086 100 mg q.d. for 28 weeks
Study: NCT03892772
Drug: SAS0421a
Approvals — FDA: no, EMA: no, PMDA: no
Description: treatment will be given for 3 days
Study: NCT03892772
Drug: SAS0421b
Approvals — FDA: no, EMA: no, PMDA: no
Description: treatment will be given for 3 days
Study: NCT03892772
Drug: SAS0421c
Approvals — FDA: no, EMA: no, PMDA: no
Description: treatment will be given for 3 days
Study: NCT03892772
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo will be given for 3 days
Study: NCT03279978
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT04215991
Drug: Standard of Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care administered will be selected by the investigator based on the suspected or confirmed pathogen(s) for the infection in accordance with local standards.
Study: NCT01247818
Drug: PH-10 (0.002% Rose Bengal)
Normalized name: prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PH-10 will be applied daily for 28 days to skin areas affected by mild to moderate psoriasis.
Study: NCT01247818
Drug: PH-10 (0.005% Rose Bengal)
Normalized name: prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PH-10 will be applied daily for 28 days to skin areas affected by mild to moderate psoriasis.
Study: NCT01247818
Drug: PH-10 (0.01% Rose Bengal)
Normalized name: prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PH-10 will be applied daily for 28 days to skin areas affected by mild to moderate psoriasis.
Study: NCT01247818
Drug: Vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: PH-10 vehicle will be applied daily for 28 days to skin areas affected by mild to moderate psoriasis.
Study: NCT00400491
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsule twice a week, identical to the cholecalciferol capsules
Study: NCT02601001
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo tablets
Study: NCT01225393
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Stable dose if not on leflunomide
Study: NCT01225393
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous repeating dose
Study: NCT01841008
Drug: Placebo : Diprobase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical treatment (tacrolimus or placebo) will be delivered to the patient by the hospital pharmacy and should be applied twice per week (3 or 4 days apart) for 24 weeks.
Study: NCT01330381
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching oral solution or oral tablets given once daily
Study: NCT02162745
Drug: Hypertonic solution (NaCl 3%)
Normalized name: Hypertonic solutions
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01369719
Drug: osveral
Approvals — FDA: no, EMA: no, PMDA: no
Description: receive 20 mg/kg daily orally
Study: NCT01257126
Drug: diclofenac potassium
Normalized name: Diclofenac Potassium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00216359
Drug: antiretroviral co-medication beside Fuzeon
Approvals — FDA: no, EMA: no, PMDA: no